Fatigue · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod probably leads to higher fatigue ‐ any grade compared with cidofovir (moderate certainty).
1 finding from 1 review
Headache · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod probably leads to higher headache ‐ any grade compared with cidofovir (moderate certainty).
1 finding from 1 review
Total serious adverse events · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in total serious adverse events compared with cidofovir (moderate certainty).
1 finding from 1 review
Treatment discontinuation · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in treatment discontinuation compared with cidofovir (moderate certainty).
1 finding from 1 review
Complete response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod leads to higher response to treatment at 5 to 6 months ‐ complete response compared with placebo (high certainty).
2 findings from 1 review
Response to treatment at 12 months ‐ overall response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod probably leads to higher response to treatment at 12 months ‐ overall response compared with placebo (moderate certainty).
1 finding from 1 review
Progression to vulval cancer at 12 months · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in progression to vulval cancer at 12 months compared with placebo (low certainty).
1 finding from 1 review
HPV DNA persistence · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod leads to lower HPV DNA persistence compared with placebo (high certainty).
1 finding from 1 review
Pain ‐ Any grade · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod leads to higher pain ‐ any grade compared with placebo (high certainty).
1 finding from 1 review
Dose reductions · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod leads to higher dose reductions compared with placebo (high certainty).
1 finding from 1 review
Response to treatment at 6 months ‐ overall response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in response to treatment at 6 months ‐ overall response compared with cidofovir (moderate certainty).
1 finding from 1 review
Pain ‐ Any grade · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dose reductions · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain ‐ Any grade · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatigue · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Headache · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean GI symptom scores · Men with prostate cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acute and late GI toxicity (grade 2+) · Men with prostate cancer
It is very uncertain whether summary of findings: Corticosteroids changes acute and late GI toxicity (grade 2+) compared with placebo (very low certainty).
1 finding from 1 review
Diarrhoea (grade 2+) · Men with prostate cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found